Related Experiment Video

Updated: Nov 20, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K

Molecular Delivery of Cytotoxic Agents via Integrin Activation

Martina Cirillo1, Daria Giacomini1

  • 1Department of Chemistry "Giacomo Ciamician", Alma Mater Studiorum University of Bologna, Via Selmi 2, 40126 Bologna, Italy.

Cancers
|January 20, 2021
PubMed

Insights

Targeting cell adhesion receptors called integrins with drug conjugates shows promise for cancer therapy. Covalent conjugates of integrin ligands and antitumor drugs improve tumor cell selectivity and may reduce side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Delivery

Background:

  • Integrins are cell adhesion receptors frequently overexpressed in tumor cells.
  • Direct integrin inhibition has shown limited success in clinical trials.
  • Integrins offer a potential target for selective delivery of cytotoxic agents.

Purpose of the Study:

  • To review recent advancements in covalent conjugates linking integrin ligands with antitumor drugs.
  • To evaluate the efficacy and selectivity of these targeted drug delivery systems.

Main Methods:

  • Development of active-targeting systems utilizing integrins as cellular entry points.
  • Covalent conjugation of cytotoxic drugs to integrin ligands, primarily RGD peptides, via specific linkers.

Main Results:

  • Covalent conjugates demonstrated enhanced selectivity towards tumor cells compared to free drugs.
  • These targeted conjugates hold potential for reduced systemic toxicity.

Conclusions:

  • Covalent conjugates of integrin ligands and antitumor drugs represent a promising strategy for targeted cancer therapy.
  • Further research into these conjugates may lead to improved treatment outcomes with fewer side effects.
Keywords:
active targetingcancerintegrinsmolecular deliveryreceptor targetingselective citotoxycity

More Related Videos

Delivery of Proteins, Peptides or Cell-impermeable Small Molecules into Live Cells by Incubation with the Endosomolytic Reagent dfTAT10:30

Delivery of Proteins, Peptides or Cell-impermeable Small Molecules into Live Cells by Incubation with the Endosomolytic Reagent dfTAT

Published on: September 2, 2015

10.5K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.1K

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.2K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
866